IT treatment with mPH-762 produced a dose-associated statistically significant increase in the mean percentage (%) CD45+ tumor immune lymphocyte infiltrate (TIL), analogous to that observed with the systemic treated anti-PD-1 control (Figure 2A). This evidence concerns the gene PTPRC and neoplasm.